BRIEF-Celcuity - Announces Phase 3 VIKTORIA-1 Trial Results For PIK3CA MT Cohort - SEC Filing

Celcuity Inc.

Celcuity Inc.

CELC

0.00

June 2 (Reuters) - Celcuity Inc CELC.O:

  • CELCUITY - ANNOUNCES PHASE 3 VIKTORIA-1 TRIAL RESULTS FOR PIK3CA MT COHORT - SEC FILING

  • CELCUITY - GEDATOLISIB-TRIPLET ORR 48.9% VERSUS 26%, MEDIAN DOR 15.7 MONTHS VERSUS 7.5 MONTHS - SEC FILING

  • CELCUITY - GEDATOLISIB REGIMENS GENERALLY WELL TOLERATED WITH MOSTLY LOW-GRADE ADVERSE EVENTS - SEC FILING

  • CELCUITY - GEDATOLISIB-TRIPLET SHOWS MEDIAN PFS OF 11.1 MONTHS VERSUS 5.6 MONTHS COMPARED TO ALPELISIB PLUS FULVESTRANT- SEC FILING

  • CELCUITY - ON TRACK FOR GEDATOLISIB COMMERCIAL LAUNCH PENDING FDA APPROVAL IN Q3 2026 - SEC FILING

  • CELCUITY - FDA GRANTS PRIORITY REVIEW TO CELCUITY'S GEDATOLISIB NDA; PDUFA DATE JULY 17, 2026 - SEC FILING

Source text: [ID:n0001493152-26-026761]

Further company coverage: CELC.O


This page is machine-translated. Sahm tries to improve but does not guarantee the accuracy and reliability of the translation, and will not be liable for any loss or damage caused by any inaccuracy or omission of the translation. *Disclaimer: The above content only represents the author's personal position and opinion and does not represent any position of Sahm Capital Financial Company and Sahm cannot confirm the authenticity, accuracy, and originality of the above content. Investors should consider the risks of investment products in light of their circumstances before making any investment decisions. When necessary, please consult a professional investment advisor. Sahm does not provide any investment advice, nor does it make any commitments and guarantees.